期刊文献+

注射用硼替佐米中异构体的检测方法研究

原文传递
导出
摘要 目的 针对注射用硼替佐米中对映异构体杂质进行分析方法建立及验证,以期对注射用硼替佐米的质控提供一定的参考.方法 拟定HPLC 色谱条件,摸索异构体提取方法,对建立的方法进行方法学验证,包括系统适用性、重复性、定量限和检测限、线性等.结果 提取出的样品检测峰型正常,且提取的较完全.该色谱条件下色谱柱的理论板数较高,分离度〉1.5.自身对照溶液连续进样6 针,其峰面积及保留时间的RSD 均〈2%.硼替佐米的最小检测限为0.192 ng,硼替佐米对映异构体的最小检测限为2.034 ng,均约相当于主成分的0.010%.硼替佐米的定量限为0.384 ng,在约相当于主成分的0.001 9%下即可被定量;硼替佐米对映异构体的定量限为4.068 ng,在约相当于主成分的0.020%下即可被定量.硼替佐米在1.003~1 003 μg/ml 范围内线性良好,硼替佐米对映异构体在1.007~1 007 μg/ml 范围内线性良好.结论 该方法异构体提取完全,峰型争产,色谱条件系统适用性好,线性良好,灵敏度高,符合方法学常规要求和异构体检测需求.
作者 陈培栋
出处 《中华临床医师杂志(电子版)》 CAS 2015年第24期183-185,共3页 Chinese Journal of Clinicians(Electronic Edition)
  • 相关文献

参考文献5

二级参考文献21

  • 1Julian Adams, Mark Behnke, Shaowu Chen, et al .Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids[J] .Bioorg Med Chem Lett, 1998, 8 (4) : 333.
  • 2Raab MS, Podar K, Breitkreutz I, et al. Multiple myeloma [J]. Lancet, 2009, 374(9686): 324-339.
  • 3Berenson JR, Yellin O, Bessudo A, et al. Phase Ⅰ/Ⅱ trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma[J]. BrJ Haematol, 2013, 160(3): 321-330.
  • 4Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma [J]. Leukemia, 2006, 20(9): 1467-1473.
  • 5Koren J, Spicka I, Straub J, et al. Retrospective analysis of the results of high-dose chemotherapy with the support of autologous blood stem cells in patients with multiple myeloma. The experience of a single centre [J]. Prague Med Rep, 2010, 111(3): 207-218.
  • 6Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as inductiontreatment prior to autologous stem- cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase Ⅲ trial [J]. J Clin Oncol, 2010, 28(30): 4621-4629.
  • 7Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma[J]. N Engl J Med, 2003, 348(26): 2609-2617.
  • 8Mateos MV, Hernandez JM, Hemandea MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study [J]. Blood, 2006, 108(7): 2165-2172.
  • 9Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tu- mor cells to chemotherapeutic agents [J]. Clin Cancer Res, 2003, 9(3): 1136-1144.
  • 10Mitsiades N, Mitsisiades CS, Richardson PG, et al. The protea- some inhibitor PS-341 potentiates sensitivity of multiple myelo- ma cells to conventional chemotherapeutic agents: therapeutic applications[J]. Blood, 2003, 101 (6): 2377-2380.

共引文献83

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部